the onset of symptoms is delayed and, therefore, the objective of starting treatment early is not achieved in most cases. Less than 30% of RA patients receive DMARD treatment in the first 3 months.\textsuperscript{7,9,10} It is necessary to implement measures that act on early diagnosis and treatment of RA, through the diffusion of knowledge relating to the disease in the general population, advertising campaigns as well as an increase in the level of knowledge regarding RA in primary care physicians.

References


Abraham Zonana Nacach,\textsuperscript{a,*} Alfredo Campaña-Parra,\textsuperscript{b} Jesús Ernesto Santana-Sahagún\textsuperscript{b}

\textsuperscript{a} Unidad de Investigación Clínica y Epidemiología, Hospital General Regional N.\textsuperscript{c} 20, Instituto Mexicano del Seguro Social, Tijuana, Baja California, Mexico

\textsuperscript{b} Consulta externa Reumatología, Hospital General Regional N.\textsuperscript{c} 20, Instituto Mexicano del Seguro Social, Tijuana, Baja California, Mexico

\textsuperscript{*} Corresponding author. E-mail address: zonanana@yahoo.com (A. Zonana Nacach).

Clinical Typology of Chronic Fatigue Syndrome: Classificatory Hypothesis\textsuperscript{1–5}

Tipología clínica del síndrome de fatiga crónica: hipótesis clasificatoria

Primary (or pure) chronic fatigue syndrome (pCFS) is a complex and severe chronic and disabling disease of unknown causes, excluding secondary chronic fatigue syndrome (sCFS) related to some other medical condition. It is characterized by intense fatigue in addition to cognitive, autonomic, neuroendocrine, immunological and musculoskeletal symptoms, which are of recent appearance and that cannot be explained by other clinical reasons, lasting for at least 6 months, is non-remitting significantly with rest and which worsens with physical or mental activity, with very slow recovery and a reduction of >50% of activities of daily living previously performed by the patient.\textsuperscript{1–4} It is diagnosed according to the 1994 Fukuda criteria,\textsuperscript{1} the Canadian consensus document published in 2003\textsuperscript{5} or, more recently, the international consensus criteria of 2011; with the name of myalgic encephalomyelitis that offers a review on its physiopathology, symptoms and treatment.\textsuperscript{5} Prevalence is estimated to be between 0.5% and 2.5% of the general population.\textsuperscript{1–5} In spite of it being recognized as a disease by the WHO since 1989, and classified with the code G93.3 in the ICD-\textsuperscript{10},\textsuperscript{5,6} and that evidence accumulated from different fields during the past 2 decades, it is possible that pCFS is still largely unknown by most health professionals.

Due to the great heterogeneity in its clinical expression and the lack of standardized instruments to order its different symptoms (according to greater or lesser frequency) and clinical presentation (distinguishing between pCFS, sCFS and Idiopathic CF), we propose a classification into clusters: I, II, IIIa, IIb and IIIc, subgrouping the main clinical conditions in a consecutive series of 199 patients (Table 1), seen in a period of time between June 2010 and February 2013 at the Chronic Fatigue Specialized Hospital Unit of the Camp de Tarragona belonging to the Hospital Universitario Joan XXIII. 84% of patients (n=167) were women (5:1). Mean age at symptom onset was 41.5 years (range 9–76). The onset of symptoms was insidious in 72.8% of patients and 71.3% had a progressive evolution of disease. At the moment of interview, 51.7% (n=103) were unemployed (65 lost their job while 38 were disabled). 8% (n=16) were retired. The pCFS criteria are valid for the diagnosis in the clinical daily practice independently of other associated criteria.\textsuperscript{5–8} Having a classification of patients with CFS will allow us to identify more homogeneous groups of patients, candidates both for more individualized diagnostic and therapeutic guidelines and which allow for better expectations. In order to correctly classify a patient with CFS, we recommend a multidisciplinary approach. In first place, the CFS diagnosis must be confirmed (family physician, internal medicine specialist and/or rheumatologist), in order to then evaluate the existence of possible associated systemic diseases or chronic local processes that have a large differential diagnosis and, finally, to perform a precise diagnosis of the disease with a psychopathological background (psychologist and/or psychiatrist). Having a clear diagnosis in each one of these 6 areas, as well as the analysis of the chronology of symptoms or processes allows the inclusion of the patient into each one of the different classification subgroups.

Table 1
Classification Subtypes of Chronic Fatigue Syndrome.

<table>
<thead>
<tr>
<th>Classification subtypes</th>
<th>Primary disease (n=73/199, 36.75%)</th>
<th>Association autoimmune chronic thyroiditis (n=38/199, 19.1%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cluster I</td>
<td>pCFS, according to the Fukuda criteria</td>
<td>None, 90/199 patients (45.2%)</td>
</tr>
<tr>
<td>Cluster II</td>
<td>Idiopathic CFS, without having the Fukuda criteria</td>
<td>None, 36/199 patients (18.1%)</td>
</tr>
<tr>
<td>Cluster IIIa</td>
<td>sCFS autoimmune disease</td>
<td>17/199 patients (8.5%)</td>
</tr>
<tr>
<td></td>
<td>secondary); References</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Classification</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cluster IIIb sCFS to other medical entities</td>
<td>40/199 patients (20.1%)</td>
</tr>
<tr>
<td></td>
<td>Cluster IIIc sCFS to psychopathologic abnormalities</td>
<td>16/199 patients (8%)</td>
</tr>
</tbody>
</table>

COPD: chronic obstructive pulmonary disease; CF: chronic fatigue; JAK2: Janus Kinase 2; OSA: obstructive sleep apnea; CFS: chronic fatigue syndrome (p: primary; s: secondary); CMPS: chronic myeloproliferative syndrome; ET: essential thrombocytosis.

References

9. Rami Qanneta, Ramon Fontova, María José Poveda, Sonia Castro

Unidad de Fatiga Crónica, Departamento de Reumatología, Hospital Universitari Joan XXIII, Tarragona, Spain

Departamento de Reumatología, Hospital Universitari Joan XXIII, Tarragona, Spain

Corresponding author.
E-mail address: rami_kanita229@hotmail.com (R. Qanneta).